A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 Oct 2017 Planned End Date changed from 1 Feb 2023 to 1 Oct 2021.
- 16 Oct 2017 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2021.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.